ID   NCC-MFS2-C1
AC   CVCL_A2EI
DR   Wikidata; Q105510292
RX   PubMed=32870449;
WW   https://en.cellline.jp/product/ncc-mfs2-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: 13 hours (PubMed=32870449).
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Thigh, hypodermis; UBERON=UBERON_0000376+UBERON_0002072.
ST   Source(s): PubMed=32870449
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 9,11
ST   D16S539: 9,12
ST   D21S11: 30
ST   D5S818: 11,12
ST   D7S820: 9,12
ST   TH01: 6
ST   TPOX: 11,12
ST   vWA: 14,17
DI   NCIt; C6496; Myxofibrosarcoma
DI   ORDO; Orphanet_79105; Myxofibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   71Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 30-01-24; Version: 6
//
RX   PubMed=32870449; DOI=10.1007/s13577-020-00420-z;
RA   Noguchi R., Yoshimatsu Y., Ono T., Sei A., Hirabayashi K., Ozawa I.,
RA   Kikuta K., Kondo T.;
RT   "Establishment and characterization of NCC-MFS2-C1: a novel
RT   patient-derived cancer cell line of myxofibrosarcoma.";
RL   Hum. Cell 34:246-253(2021).
//